Literature DB >> 30851300

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.

Yaowei Zhu1, Joseph C Marini2, Michael Song2, Bruce Randazzo3, Yaung-Kaung Shen2, Shu Li2, Honghui Zhou2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30851300     DOI： 10.1016/j.jid.2019.02.018

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  4 in total

Review 1.  Immunogenicity of Biologic and Biosimilar Therapies for Psoriasis and Impact of Novel Immunoassays for Immunogenicity Detection.

Authors:  Courtney E Heron; Rima I Ghamrawi; Esther A Balogh; Steven R Feldman
Journal:  Am J Clin Dermatol       Date:  2020-11-09       Impact factor: 7.403

Review 2.  Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis.

Authors:  Jeremy G Light; Jennifer J Su; Steven R Feldman
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-01-15

3.  Immunogenicity to biological drugs in psoriasis and psoriatic arthritis.

Authors:  Fernando Valenzuela; Rodrigo Flores
Journal:  Clinics (Sao Paulo)       Date:  2021-10-01       Impact factor: 2.365

Review 4.  Guselkumab for the Treatment of Palmoplantar Pustulosis: A Japanese Perspective.

Authors:  Toshiyuki Yamamoto
Journal:  Clin Pharmacol       Date:  2021-06-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.